Literature DB >> 12083242

Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen.

Elise M Beltrami1, Chi-Cheng Luo, Nicolas de la Torre, Denise M Cardo.   

Abstract

We documented a case of occupational human immunodeficiency virus (HIV) despite postexposure prophylaxis (PEP) with a combination drug regimen after percutaneous injury with a needle from a sharps disposal container in the hospital room of an HIV-infected patient. This failure of PEP with a combination drug regimen may have been related to antiretroviral drug resistance, other factors, or both. This case highlights the importance of preventing injury to prevent occupational transmission of HIV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12083242     DOI: 10.1086/502065

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2015-01       Impact factor: 5.078

2.  [HIV prophylaxis kits. A concept for emergency treatment in the context of postexposure prophylaxis].

Authors:  S Wicker; F Walcher; S Wutzler; I Marzi; C Stephan
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

3.  Timing, adherence, resistance, and ... persistence? new insight into the mechanisms of failure of HIV type 1 postexposure prophylaxis.

Authors:  Gustavo H Kijak; Jerome H Kim
Journal:  J Infect Dis       Date:  2013-09-09       Impact factor: 5.226

Review 4.  Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis.

Authors:  Douglas S Krakower; Sachin Jain; Kenneth H Mayer
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

Review 5.  Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Authors:  Susan E Beekmann; David K Henderson
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

6.  Best practice for needlestick injuries.

Authors:  S Wicker; F Walcher; S Wutzler; C Stephan; I Marzi
Journal:  Eur J Trauma Emerg Surg       Date:  2014-01-31       Impact factor: 3.693

Review 7.  Management of occupational and nonoccupational postexposure HIV prophylaxis.

Authors:  Mitchell H Katz; Julie Louise Gerberding
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.495

8.  Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions.

Authors:  James I Brooks; Harrison Niznick; Marianna Ofner; Harriet Merks; Jonathan B Angel
Journal:  BMC Infect Dis       Date:  2013-10-30       Impact factor: 3.090

Review 9.  Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting.

Authors:  Vincenzo Puro; Stefania Cicalini; Gabriella De Carli; Fabio Soldani; Francisco Antunes; Ulla Balslev; Josip Begovac; Enos Bernasconi; José L Boaventura; Magda Campins Martí; Rok Civljak; Barry Evans; Patrick Francioli; Fiona Genasi; Christine Larsen; Florence Lot; Suzanne Lunding; Ulrich Marcus; Alvaro A Pereira; Tania Thomas; Slavko Schonwald; Giuseppe Ippolito
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 12.434

10.  Expert consensus statement on the science of HIV in the context of criminal law.

Authors:  Françoise Barré-Sinoussi; Salim S Abdool Karim; Jan Albert; Linda-Gail Bekker; Chris Beyrer; Pedro Cahn; Alexandra Calmy; Beatriz Grinsztejn; Andrew Grulich; Adeeba Kamarulzaman; Nagalingeswaran Kumarasamy; Mona R Loutfy; Kamal M El Filali; Souleymane Mboup; Julio Sg Montaner; Paula Munderi; Vadim Pokrovsky; Anne-Mieke Vandamme; Benjamin Young; Peter Godfrey-Faussett
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.